Cetuximab (Erbitux) Pharmacokinetic ELISA (RUO)

SKU:BHE18300003
Overview
Click light‑blue chips for details
Sandwich ELISA for quantifying free Cetuximab (Erbitux) — a chimeric anti-EGFR IgG1 mAb — in research serum and plasma. Detection range 1.56–50 ng/mL; assay time 2.5 h. Validated for human, mouse, and rat matrices. For research use only.
Target Cetuximab (Erbitux)
Reactivity Human, mouse, rat
Detection Range 50ng/ml - 1.56ng/ml
Assay Time 2.5 hours
Sample Type(s) Serum Plasma
Assay Type Direct sandwich ELISA
Options selector
Catalog no. Size
EL-1611-031-96WELLSX1 96 wells × 1
Available Options

Select from the available variant options shown on this page. Availability and lead time can vary by option.

  • Options: Size (96 wells × 1).
  • Lead time: options listed as “In Stock at Manufacturer” typically ship in 3-5business days.
  • Storage: -20°C, 1 year; cold-chain shipment (typically with ice packs) is expected.
  • Please ensure someone is available to receive cold-chain deliveries promptly.
  • Sales terms and conditions: Please review prior to ordering.
Field Specification
Mfr No EL-1611-031
Assay Time
  • 2.5 hours
Assay Type
  • Direct sandwich ELISA
Detection Method
  • Peroxidase / OD450 
Detection Range 50ng/ml - 1.56ng/ml
Gene ID 1956
Product Type
  • ELISA Kits
  • Biologic Drug Research Kits
Reactivity
  • Human, mouse, rat
Sample Type(s) Serum Plasma
Storage -20C, 1 year
Target Cetuximab (Erbitux)

Background

Cetuximab (Erbitux) Pharmacokinetic is a biological molecule commonly studied in life science research. It is commonly used as a molecular readout in mechanistic and biomarker-focused studies.

Biological context

Researchers often monitor Cetuximab (Erbitux) Pharmacokinetic in Serum Plasma to better understand themes such as mechanistic biology studies, biomarker-focused profiling, and disease-model research. In many model systems, measured levels can shift with physiology, experimental perturbation, or disease-associated changes, making careful biological interpretation important.

Interpreting changes in measured levels

Depending on sample matrix and study design, increases or decreases in Cetuximab (Erbitux) Pharmacokinetic may reflect differences in expression, secretion, turnover, or compartmentalization rather than a single mechanism. Interpretation is typically strengthened by evaluating related molecules (for example, complementary pathway markers and controls appropriate to the biological model) and by keeping pre-analytical variables consistent across groups.

Why quantitative measurements are widely used

Quantitative immunoassays are widely used for measuring proteins and biomarkers in complex samples, enabling comparisons across experimental groups and time points. When integrating results with other readouts, consider species biology, sample type, and the broader pathway context that Cetuximab (Erbitux) Pharmacokinetic participates in.

What biological matrices are compatible with this pharmacokinetic ELISA?

This kit is validated for use with human, mouse, and rat serum and plasma (EDTA or heparin). Other matrices (e.g., tissue homogenates or cell culture supernatants) may require additional validation. Samples should be diluted into the assay diluent at the manufacturer-recommended minimum required dilution (MRD) prior to testing.

What is the detection principle of this pharmacokinetic ELISA?

The assay uses a sandwich enzyme immunoassay (ELISA) format. Anti-drug antibodies are pre-coated onto a 96-well microplate to capture the target biologic drug from the sample. A secondary HRP-conjugated detection antibody is then added, followed by TMB substrate. Color development is proportional to drug concentration and is quantified at OD 450 nm against a standard curve.

Does this kit measure free drug or total drug concentration?

This kit is configured to measure free (unbound) drug — the pharmacologically active fraction not complexed with target antigen. For total drug quantification (free + antigen-bound), a different assay format using non-competing anti-idiotypic antibodies is required. Please consult the datasheet or contact us for guidance specific to your study design.

How should I prepare serum or plasma samples before running the assay?

Allow frozen samples to thaw completely at room temperature and mix gently by inversion — do not vortex. Centrifuge at 2,000–3,000 × g for 10 min if particulates are visible. Dilute samples in assay diluent per the recommended MRD. Avoid repeated freeze-thaw cycles; aliquot samples upon receipt. Hemolyzed or highly lipemic samples may interfere with OD readings.

Can this kit be used for therapeutic drug monitoring (TDM)?

This kit is designed for Research Use Only (RUO) and is not CE-IVD certified or FDA-cleared for clinical diagnostic use. It is well-suited for preclinical PK studies, biosimilar characterization, and research-based TDM in academic and pharmaceutical R&D settings. For clinical patient monitoring, a certified diagnostic assay should be used.

Are biosimilars or biobetters of this drug detectable with this kit?

Yes, in most cases. Because this kit uses antibodies that recognize conserved structural epitopes of the biologic drug, biosimilars and biobetters sharing the same target binding domain are generally detectable. However, cross-reactivity and assay performance should be independently verified for each biosimilar, as minor structural differences may affect antibody recognition and signal output.

What is the shelf life and storage requirement for this kit?

Store the complete kit at −20°C with a shelf life of 12 months from the date of manufacture (see label). Once thawed, components should be used within the timeframe specified in the datasheet. Do not freeze the 96-well plate after initial use. Reconstituted standards should be aliquoted and stored at −20°C; avoid repeated freeze-thaw cycles.

How should I construct and validate my standard curve?

Run a minimum of a 7- or 8-point standard curve in duplicate at each assay run, using the provided recombinant calibrators diluted in assay diluent. Fit the curve using a 4-parameter logistic (4PL) regression model. Acceptance criteria typically require R² ≥ 0.99 and back-calculated standard concentrations within ±20% of nominal (±25% at LLOQ). Do not extrapolate beyond the verified quantification range.

Can’t Find What You’re Looking For? We can help you source the best match or customize an ELISA solution for your study. Options may include alternative target synonyms, different species reactivity, sample type/matrix compatibility (serum/plasma/lysate/supernatant), assay format (sandwich/competitive), sensitivity/range, detection chemistry (colorimetric/fluorescent/chemiluminescent), plate format (pre-coated/uncoated, strips vs full plate), and bulk or custom packaging. Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.

  1. Pérez-Robles R et al. “Development and use of specific ELISA methods for quantifying the biological activity of bevacizumab, cetuximab and trastuzumab in stability studies.” Journal of Pharmaceutical and Biomedical Analysis, 2016. PMID: 27296731
  2. Cézé N et al. “An enzyme-linked immunosorbent assay for therapeutic drug monitoring of cetuximab.” Therapeutic Drug Monitoring, 2009. PMID: 19730278

Get a Quote

Please use this form for bulk quantity requests or customized products.

Contact Information

Product Information

Try Celltrypse Free – Request Your Sample Today

Experience the power of Celltrypse™, c-LEcta's innovative enzyme solution for gentle and efficient cell dissociation. Request your free sample and discover a superior alternative for your cell culture workflows.

Try Celltrypse Free – Request Your Sample Today

Try Celltrypse Free – Request Your Sample Today

Experience the power of Celltrypse™, c-LEcta's innovative enzyme solution for gentle and efficient cell dissociation. Request your free sample and discover a superior alternative for your cell culture workflows.

Try Celltrypse Free – Request Your Sample Today